openPR Logo
Press release

Insulin Biosimilars Market Witness Comprehensive Growth by 2026

06-22-2018 08:20 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Future Market Insights

Insulin Biosimilars Market Witness Comprehensive Growth

A new race has been initiated between biosimilar and branded drug manufacturers to gain maximum revenue share from insulin market. The upcoming three years are very crucial for insulin manufacturers, as most of the branded insulin are going to be off patent which would results into the loss of around US$53 Bn revenue for branded manufacturers in 2016. Generic manufacturers are expected to take smaller chunk of this amount owing to their local presence which would restrain them take share from other markets. In such dynamic situation, the original drug manufacturers are seeking for plan B to sustain their hold in the market. As a result, these companies are now integrated with biosimilar manufacturers through agreement, alliance. Moreover, legal troubles pertaining patent infringement is hampering the development insulin Biosimilars. In order to overcome such infringement issues, the companies are now collaborating with each other to develop biosimilars versions of insulin. Recent example of global collaboration agreement between Mylan N.V. and Momenta Pharmaceuticals, Inc. has provided a competitive advantage to Mylan by increasing the number of insulin biosimlars under development. This collaboration will capitalized Mylan’s existing portfolio of biologics and insulin analog development.

Request For Sample @https://www.futuremarketinsights.com/reports/sample/rep-gb-1883

Insulin Biosimilars Market: Drivers and Restraints

Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.

Insulin Biosimilars Market: Segmentation

The global market for insulin Biosimilar is segmented on the basis of disease indication and geography.

On the basis of disease indication, the global insulin Biosimilar market is segmented as,

Type I Diabetes

Type II Diabetes

Insulin Biosimilars Market: Overview

Development of clinically proven insulin Biosimilar will pave the road for new entrants. The upcoming patent expiration of blockbuster insulin drugs will open a new avenue and unprecedented opportunities for biosimilar development and manufacturing companies. The cost of insulin biosimilar is currently high owing to stringent adherence requirements in terms of complex regulations and manufacturing and operations. Prices of biosimilar drugs are expected decreased by an average of 20% as compared to branded drugs.

Insulin Biosimilars Market: Region-wise Outlook

Geographically, the global insulin biosimilar market is segmented into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding Japan, Japan, Middle East and Africa. Among all the regions, North America will continue to lead the global market for insulin biosimilars market due to high demand for insulin. Europe insulin market is expected to account for second largest share in global market primarily due to early approval for biosimilar which is expected to fuel the market growth. Asian companies are competing on the basis of price and has patient pool suffering diabetes. Hence, the Asia Pacific insulin biosimilar market is expected to witness fastest growth in overall market over the forecast period.

Request For TOC @ https://www.futuremarketinsights.com/askus/rep-gb-1883

Insulin Biosimilars Market: Key Players

Key players operating in the global insulin biosimilar market are Eli Lilly & Co., Boehringer Ingelheim, Merck & Co., Pfizer Inc., Biocon, Mylan N.V. and others

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature.
FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: http://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Insulin Biosimilars Market Witness Comprehensive Growth by 2026 here

News-ID: 1093199 • Views:

More Releases from Future Market Insights

AI in IoT Market Set to Reach USD 172.8 Billion by 2035 with 6.4% CAGR Amid Rising Digital Transformation
AI in IoT Market Set to Reach USD 172.8 Billion by 2035 with 6.4% CAGR Amid Risi …
The AI in IoT market is witnessing rapid expansion as enterprises across industries increasingly integrate artificial intelligence with Internet of Things (IoT) systems. Valued at USD 92.9 billion in 2025, the market is projected to reach USD 172.8 billion by 2035, representing a compound annual growth rate of 6.4%. The integration of AI into IoT infrastructure enables predictive analytics, real-time monitoring, and automated control across multiple applications, transforming how businesses
Catalog Management System Market Poised to Reach USD 4.2 Billion by 2035 with Advanced Technology Integration
Catalog Management System Market Poised to Reach USD 4.2 Billion by 2035 with Ad …
The catalog management system (CMS) market is experiencing steady and strategic growth, with its value projected to rise from USD 1.9 billion in 2025 to USD 4.2 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.1%. The market expansion is primarily fueled by businesses' growing need for centralized product information, streamlined digital operations, and enhanced customer experiences across increasingly complex sales channels. As e-commerce continues to penetrate global
HIFI Electronics Market Set to Double by 2035, Driven by Premium Audio and Technological Innovation
HIFI Electronics Market Set to Double by 2035, Driven by Premium Audio and Techn …
The global HIFI electronics market is poised for remarkable growth over the next decade, projected to expand from USD 17,243.4 million in 2025 to USD 37,227.2 million by 2035. This impressive growth trajectory, representing an absolute increase of nearly USD 19,983.8 million and a compound annual growth rate (CAGR) of 8%, reflects the rising global appetite for premium audio experiences and high-fidelity sound reproduction across personal and professional applications. The expansion
Interrogation Table Market to Reach USD 435.7 Million by 2035, Driven by Security Infrastructure Expansion
Interrogation Table Market to Reach USD 435.7 Million by 2035, Driven by Securit …
The global interrogation table market, valued at USD 321.1 million in 2025, is set to grow steadily to USD 435.7 million by 2035, registering a moderate CAGR of 3.1%. This trajectory reflects a market gradually approaching maturity, where incremental demand for specialized security furniture outweighs rapid expansion. The early stage from 2025 to 2028 is expected to see modest increases in annual revenues, primarily linked to new infrastructure development across

All 5 Releases


More Releases for Biosimilar

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of